• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性淋巴细胞白血病患者的B细胞亚群与免疫检查点表达

B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia.

作者信息

Ntsethe Aviwe, Mkhwanazi Zekhethelo Alondwe, Dludla Phiwayinkosi Vusi, Nkambule Bongani Brian

机构信息

School of Laboratory Medicine and Medical Sciences (SLMMS), University of KwaZulu-Natal, Durban 4000, South Africa.

Cochrane South Africa, South African Medical Research Council, Tygerberg 7505, South Africa.

出版信息

Curr Issues Mol Biol. 2024 Feb 23;46(3):1731-1740. doi: 10.3390/cimb46030112.

DOI:10.3390/cimb46030112
PMID:38534728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10969689/
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by dysfunctional B cells. Immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) are upregulated in patients with CLL and may correlate with prognostic markers such as beta-2 microglobulin (B2M). The aim of this study was to evaluate the levels of immune checkpoints on B cell subsets and to further correlate them with B2M levels in patients with CLL. We recruited 21 patients with CLL and 12 controls. B cell subsets and the levels of immune checkpoint expression were determined using conventional multi-color flow cytometry. Basal levels of B2M in patients with CLL were measured using an enzyme-linked immunosorbent assay. Patients with CLL had increased levels of activated B cells when compared to the control group, < 0.001. The expression of PD-1 and CTLA-4 were increased on activated B cells and memory B cells, < 0.05. There were no associations between B2M levels and the measured immune checkpoints on B cell subsets, after adjusting for sex and age. In our cohort, the patients with CLL expressed elevated levels of PD-1 and CTLA-4 immune checkpoints on activated and memory B cell subsets. However, there was no correlation between these immune checkpoint expressions and B2M levels.

摘要

慢性淋巴细胞白血病(CLL)的特征是B细胞功能失调。免疫检查点分子,如细胞毒性T淋巴细胞相关蛋白4(CTLA-4)和程序性死亡蛋白1(PD-1),在CLL患者中上调,并且可能与β2微球蛋白(B2M)等预后标志物相关。本研究的目的是评估B细胞亚群上免疫检查点的水平,并进一步将它们与CLL患者的B2M水平相关联。我们招募了21例CLL患者和12名对照。使用传统的多色流式细胞术确定B细胞亚群和免疫检查点表达水平。使用酶联免疫吸附测定法测量CLL患者的B2M基础水平。与对照组相比,CLL患者的活化B细胞水平升高,<0.001。活化B细胞和记忆B细胞上PD-1和CTLA-4的表达增加,<0.05。在调整性别和年龄后,B2M水平与B细胞亚群上测量的免疫检查点之间没有关联。在我们的队列中,CLL患者在活化和记忆B细胞亚群上表达升高水平的PD-1和CTLA-4免疫检查点。然而,这些免疫检查点表达与B2M水平之间没有相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/7fde187470dc/cimb-46-00112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/d7eea34639c8/cimb-46-00112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/be13fe9c2744/cimb-46-00112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/d5611432b8e0/cimb-46-00112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/7fde187470dc/cimb-46-00112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/d7eea34639c8/cimb-46-00112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/be13fe9c2744/cimb-46-00112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/d5611432b8e0/cimb-46-00112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed4/10969689/7fde187470dc/cimb-46-00112-g004.jpg

相似文献

1
B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者的B细胞亚群与免疫检查点表达
Curr Issues Mol Biol. 2024 Feb 23;46(3):1731-1740. doi: 10.3390/cimb46030112.
2
Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.慢性淋巴细胞白血病患者中 BTLA 和 CTLA-4 免疫检查点分子的异常表达。
J Immunol Res. 2020 Jul 28;2020:6545921. doi: 10.1155/2020/6545921. eCollection 2020.
3
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.泽布替尼对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者免疫细胞的影响。
Hematol Oncol. 2019 Oct;37(4):392-400. doi: 10.1002/hon.2667. Epub 2019 Sep 13.
4
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.慢性淋巴细胞白血病中的T细胞表现出免疫检查点和激活标志物的表达失调。
Haematologica. 2017 Mar;102(3):562-572. doi: 10.3324/haematol.2016.151100. Epub 2016 Dec 7.
5
Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8 T cells in early clinical stages of chronic lymphocytic leukemia.阻断 PD-1 和 TIM-3 免疫检查点并不能恢复慢性淋巴细胞白血病早期临床阶段耗尽的 CD8 T 细胞的功能。
Immunol Res. 2020 Oct;68(5):269-279. doi: 10.1007/s12026-020-09146-4.
6
Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.通过 Notch-c-Myc-EZH2 致癌信号通路的基质触发来控制 CLL 细胞中的 PD-L1 表达。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-001889.
7
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.组蛋白去乙酰化酶 6 抑制减轻慢性淋巴细胞白血病诱导的 T 细胞功能障碍,并增强 Eμ-TCL1 模型中的免疫检查点阻断疗效。
Front Immunol. 2020 Nov 23;11:590072. doi: 10.3389/fimmu.2020.590072. eCollection 2020.
8
PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.PD-1 和 PD-L1 基因表达及其与慢性淋巴细胞白血病中 Epstein-Barr 病毒感染的关系。
Clin Transl Oncol. 2021 Nov;23(11):2309-2322. doi: 10.1007/s12094-021-02657-y. Epub 2021 Jun 13.
9
Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.慢性淋巴细胞白血病患者外周血和骨髓中T淋巴细胞和B淋巴细胞表面CD25和CD69的表达与该疾病既定预后因素之间的关系。
Adv Clin Exp Med. 2018 Jul;27(7):987-999. doi: 10.17219/acem/74437.
10
Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?免疫缺陷患者血液系统恶性肿瘤的发生发展中,免疫检查点紊乱与EB病毒再激活有关联吗?
Cancers (Basel). 2023 Sep 29;15(19):4786. doi: 10.3390/cancers15194786.

引用本文的文献

1
Impact of Protein Kinase C Activation and Monoclonal Antibodies on Immune Checkpoint Regulation and B Cell Function in Patients with Chronic Lymphocytic Leukemia.蛋白激酶C激活和单克隆抗体对慢性淋巴细胞白血病患者免疫检查点调节及B细胞功能的影响
Biomedicines. 2025 Mar 18;13(3):741. doi: 10.3390/biomedicines13030741.

本文引用的文献

1
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.泽布替尼或伊布替尼用于复发或难治性慢性淋巴细胞白血病
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
2
Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors.靶向治疗、抗 CD20 单克隆抗体化疗免疫治疗慢性淋巴细胞白血病患者的预后标志物:预后因素的系统评价和荟萃分析。
BMC Cancer. 2022 Nov 25;22(1):1218. doi: 10.1186/s12885-022-10223-0.
3
B-Cell-Based Immunotherapy: A Promising New Alternative.
基于B细胞的免疫疗法:一种有前景的新选择。
Vaccines (Basel). 2022 May 31;10(6):879. doi: 10.3390/vaccines10060879.
4
B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments.肿瘤微环境中 B 细胞异质性、可塑性和功能多样性。
Oncogene. 2021 Jul;40(29):4737-4745. doi: 10.1038/s41388-021-01918-y. Epub 2021 Jun 29.
5
CTLA-4 expression by B-1a B cells is essential for immune tolerance.B-1a 细胞表达 CTLA-4 对于免疫耐受至关重要。
Nat Commun. 2021 Jan 22;12(1):525. doi: 10.1038/s41467-020-20874-x.
6
Ethnic and geographic diversity of chronic lymphocytic leukaemia.慢性淋巴细胞白血病的种族和地域多样性。
Leukemia. 2021 Feb;35(2):433-439. doi: 10.1038/s41375-020-01057-5. Epub 2020 Oct 19.
7
Revisiting the PD-1 pathway.重新审视PD-1通路。
Sci Adv. 2020 Sep 18;6(38). doi: 10.1126/sciadv.abd2712. Print 2020 Sep.
8
Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.慢性淋巴细胞白血病患者中 BTLA 和 CTLA-4 免疫检查点分子的异常表达。
J Immunol Res. 2020 Jul 28;2020:6545921. doi: 10.1155/2020/6545921. eCollection 2020.
9
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
10
A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex.激活标志物 CD86 与免疫检查点标志物 B 和 T 淋巴细胞衰减因子(BTLA)的组合表明,在健康献血者中,B 细胞亚型存在一种假定的允许激活状态,这种状态与年龄和性别无关。
BMC Immunol. 2020 Mar 20;21(1):14. doi: 10.1186/s12865-020-00343-2.